1 unchanged sentence
Use of Proceeds from Registered Securities
−Removed: On October 4, 2016, we completed the IPO of our common stock, in which we issued and sold an aggregate of 4,830,000 shares of common stock (including 630,000 shares issued and sold on October 7, 2016 pursuant to the underwriters’ exercise in full of their option to purchase additional shares) at a public offering price of $9.00 per share.
+Added: On October 4, 2016, we completed the IPO of our common stock, in which we issued and sold an aggregate of 4.8 million shares of common stock (including 630,000 shares issued and sold on October 7, 2016 pursuant to the underwriters’ exercise in full of their option to purchase additional shares) at a public offering price of $9.00 per share.
We received net proceeds from the IPO of approximately $36.0 million, after deducting underwriting discounts and commissions and offering expenses paid or payable by us of approximately $4.4 million.
1 unchanged sentence
333-213469), as amended, and the final prospectus dated September 28, 2016 included in such registration statement, or the Prospectus.
−Removed: To date, we have used $28.8 million of the net proceeds from the IPO, of which, $4.5 million was used for contributions to our joint venture, FF Gene Biotech, in partial satisfaction of our contribution obligations under the cooperation agreement for the joint venture and $24.3 million was used to fund the Company’s operations.
−Removed: All other net proceeds from the IPO are invested in investment-grade and interest-bearing securities, such as money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S.
+Added: To date, we have used $28.8 million of the net proceeds from the IPO, of which, $4.5 million was used for contributions to FF Gene Biotech prior to the FF Gene Biotech Acquisition and $24.3 million was used to fund the Company’s operations.
+Added: All other net proceeds from sales of our common stock are invested in investment-grade and interest-bearing securities, such as equity securities, corporate bonds, municipal bonds, and U.S.
+Added: government and U.S.
+Added: agency debt securities .
There has been no material change in the planned use of proceeds from the IPO from that described in the Prospectus.
5 unchanged sentences
There has been no material change in the planned use of proceeds as described in the prospectus supplements and accompanying base prospectus.
−Removed: On November 13, 2019, we entered into a purchase agreement with Piper, as representative of the several underwriters, pursuant to which we sold 2,673,750 shares of our common stock at a price of $10.52 per share, with a public offering price of $11.25 per share.
+Added: On November 13, 2019, we entered into a purchase agreement with Piper, as representative of the several underwriters, pursuant to which we sold 2.7 million shares of our common stock at a price of $10.52 per share, with a public offering price of $11.25 per share.
We received net proceeds of approximately $27.6 million, after deducting underwriting discounts and commissions and offering expenses paid or payable by us of approximately $2.4 million.
11 unchanged sentences
During the year ended December 31, 2020, we sold an aggregate of 2.0 million shares of our common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $48.70 per share, which resulted in $99.1 million of net proceeds to the Company.
−Removed: During the six months ended June 30, 2021, we sold approximately 961,000 shares of our common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $60.56, which resulted in $58.2 million of net proceeds to the Company.
+Added: During the nine months ended September 30, 2021, we sold approximately 961,000 shares of our common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $60.56, which resulted in $58.2 million of net proceeds to the Company.
Shares sold under the November 2020 Equity Distribution Agreement were offered and sold pursuant to our registration statement on Form S-3 (File No.
4 unchanged sentences
Exhibit Title
−Removed: Incorporated by Reference
−Removed: Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd.
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10 unchanged sentences
Furnished herewith.
−Removed: Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
−Removed: The Company hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.
−Removed: Confidential treatment has been granted with respect to portions of this exhibit pursuant to Rule 24b-2 under the Exchange Act, and these confidential portions have been redacted from the version of this agreement that is incorporated by reference in this report.
−Removed: A complete copy of this exhibit, including the redacted portions, has been separately furnished to the SEC.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
FULGENT GENETICS, INC.
−Removed: August 9, 2021
+Added: November 9, 2021
/s/ Ming Hsieh
1 unchanged sentence
(principal executive officer)
−Removed: August 9, 2021
+Added: November 9, 2021
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.